Daiichi Pharm, Fujitsu in genetic data tie-up

By : |October 30, 2000 0

TOKYO: Japanese drug maker Daiichi Pharmaceutical Co. Ltd. and electronics
manufacturer Fujitsu Ltd. said on Monday they had agreed to jointly develop
medical products using genetic data.

Under the five-year project, the two firms and unlisted Japanese
biotechnology start-up Celestar Lexico-Sciences Inc., owned 20 per cent by
Fujitsu, will use a computer program they developed to analyze genetic

Daiichi Pharmaceutical plans to invest 15 billion yen ($138 million) over the
next five years.

The firms aim to find substances effective in fighting diseases, including
cancer, dementia and infectious diseases by combining Fujitsu’s information
technology and Daiichi’s ability to develop medicine, the companies said.

The plan reflected accelerating cooperation between such companies to sort
huge amounts of genetic data, they said.

"We are confident the joint research will bear fruit not only in the
area of manufacturing new medicine, but also a wider range of businesses such as
treatment of genes," the companies said in a statement.

The news attracted buying in Daiichi Pharm on the Tokyo Stock Exchange. Its
shares ended the morning 3.58 per cent higher at 2,895 yen. Fujitsu inched up
0.15 per cent to 1,976 yen.

(C) Reuters Limited 2000.

No Comments so fars

Jump into a conversation

No Comments Yet!

You can be the one to start a conversation.